Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.